Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Report 2026

The methicillin-resistant staphylococcus aureus (MRSA) testing market size has grown strongly in recent years. It will grow from $3.95 billion in 2025 to $4.18 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising prevalence of hospital-acquired infections, increasing awareness of antibiotic resistance, expansion of diagnostic laboratory infrastructure, growth in hospital infection control programs, increasing use of culture-based diagnostic methods.

The methicillin-resistant staphylococcus aureus (MRSA) testing market size is expected to see strong growth in the next few years. It will grow to $5.28 billion by 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to rising adoption of rapid molecular diagnostic technologies, increasing investment in precision medicine and pathogen genomics, expansion of automated laboratory systems, growing demand for real-time infection surveillance, stricter regulatory focus on antimicrobial resistance control. Major trends in the forecast period include rising adoption of rapid molecular diagnostics for antibiotic resistance detection, increasing use of point-of-care MRSA testing in hospitals, growing implementation of automated microbiology workflows in diagnostic laboratories, expansion of infection surveillance programs in healthcare facilities, increasing demand for multiplex assays for hospital-acquired infection screening.

The increasing prevalence of hospital-acquired infections is expected to propel the growth of the methicillin-resistant Staphylococcus aureus (MRSA) testing market going forward. Hospital-acquired infections (HAIs) are secondary infections that patients contract while receiving medical or surgical treatment within a healthcare facility. This prevalence is rising globally, contributing to the increasing complexity of medical procedures and the growing number of immunocompromised patients, which create greater opportunities for opportunistic pathogens to colonize. MRSA testing supports the management of these infections by enabling clinicians to identify colonized patients at an early stage and implement isolation protocols to prevent facility-wide transmission. For instance, in August 2025, according to the Health Security Agency, a UK-based national executive agency, the overall reported MRSA bacteremia cases reached 81, representing an 8% increase compared to 75 cases in August 2024. Therefore, the increasing prevalence of hospital-acquired infections is propelling and supporting the growth of the MRSA testing market.

Leading companies operating in the methicillin-resistant Staphylococcus aureus (MRSA) testing market are focusing on integrating artificial intelligence in testing, such as AI-powered imaging analysis, to gain a competitive advantage. AI-powered imaging analysis uses artificial intelligence algorithms to interpret bacterial growth patterns on chromogenic media plates automatically and accurately in MRSA screening workflows. For example, in May 2023, Becton, Dickinson and Company (BD), a US-based medical technology company, received FDA 510(k) clearance for the BD Kiestra MRSA Imaging application. This application automates Petri dish inspection for mauve-colored MRSA colonies, enables batch review of negative results, and integrates with BD Synapsys Informatics for efficient worklist organization. Laboratories benefit from reduced turnaround times, minimized labor burdens, and reallocation of staff to complex analyses.

In May 2024, Bruker Corporation, a US-based provider of in-vitro diagnostics, molecular diagnostics, and clinical testing solutions, acquired the molecular diagnostics division of ELITechGroup for an undisclosed value. Through this acquisition, Bruker seeks to enhance its molecular diagnostics capabilities by integrating PCR-based infectious disease testing platforms that enable detection of infectious diseases, including hospital-acquired infections such as Methicillin-resistant Staphylococcus aureus (MRSA), thereby strengthening its position in the molecular diagnostics and clinical microbiology sectors. ELITechGroup is a France-based provider of molecular diagnostic solutions that offers PCR-based testing systems for infectious disease detection and clinical microbiology applications in hospital and laboratory environments.

Major companies operating in the methicillin-resistant staphylococcus aureus (mrsa) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, bioMérieux SA, Hologic Inc., QuidelOrtho Corporation, Bruker Corporation, Bio-Rad Laboratories Inc., QIAGEN N. V., Randox Laboratories Ltd., SD Biosensor Inc., Seegene Inc., Hardy Diagnostics Inc., Alifax S. r. l., Ganesh Diagnostic and Imaging Centre Pvt. Ltd., Uniogen Oy, 3B BlackBio Dx Limited, Orange Health Labs Private Limited.

North America was the largest region in the methicillin-resistant staphylococcus aureus (MRSA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (MRSA) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the methicillin-resistant staphylococcus aureus (MRSA) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The methicillin-resistant staphylococcus aureus (MRSA) testing market consists of revenues earned by entities by providing services such as hospital laboratory testing, diagnostic lab services, point-of-care testing services, and infection screening programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The methicillin-resistant staphylococcus aureus (MRSA) testing market also includes sales of PCR test kits, culture media and chromogenic agar plates, automated diagnostic instruments, reagents, assay kits, and control materials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.